Luciole Medical AG Appoints Dr. C.A. Izeboud to its Board of Directors

— Dr. C.A. (Oscar) Izeboud, Managing Director at NIBC Bank N.V.,
strengthens Board with first-hand experience in medtech and financial
markets —

ZÜRICH–(BUSINESS WIRE)–Luciole Medical AG announced today the appointment of C. A. (Oscar)
Izeboud, Ph.D. to its Board of Directors. Dr. Izeboud currently leads
the Life Sciences and Equities Markets at NIBC Bank N.V. in Amsterdam
and brings to Luciole his in-depth knowledge of financial markets within
the healthcare and life sciences sectors, which will be advantageous as
Luciole Medical continues to develop its innovative products to measure
brain oxygenation levels.

“Being able to recruit Oscar to our Board is a great achievement for
Luciole Medical and an important step in our strategy to establish the
company as the leading developer of innovative solutions to monitor and
evaluate brain function in patients,” commented Dr. Philippe Dro, CEO of
Luciole Medical. “Given Oscar’s impressive track record in the financial
and healthcare industries, we are honored to welcome him to Luciole
Medical and look forward to his contributions as we continue to position
the company and its technology for success.”

Dr. C. A. (Oscar) Izeboud is currently Managing Director at NIBC Bank
N.V. in Amsterdam, where he leads its corporate finance and capital
markets services. Before joining NIBC Bank, he successfully developed
the Life Sciences and Healthcare practice of Kempen & Co., a Dutch
merchant bank. During his tenure at Kempen & Co. and NIBC Bank, Dr.
Izeboud was instrumental in numerous public and private transactions in
Europe and the US. Prior to entering the banking industry, Dr. Izeboud
served as the Director of Business Development at the biotechnology
company, Crucell, which was later acquired by Johnson & Johnson in 2011.
He holds a Ph.D. in immunopharmacology from the University of Utrecht in
the Netherlands.

“Luciole Medical’s next-generation devices are addressing an area of
immense medical need, enabling clinicians to monitor a patient’s brain
function in real time and make informed, quick decisions that can be
vital for survival,” added Dr. Izeboud. “I am impressed with what the
Luciole Medical team has achieved thus far and am looking forward to
contributing to Luciole’s development.”

Luciole Medical has developed a technology platform that uses the
absorbance and transmittance properties of light at the near-infrared
spectral range to measure brain oxygenation levels and cerebral blood
flow, critical parameters necessary for proper brain function. Luciole
Medical’s first product developed using the platform, called RheoProbe,
is a minimally invasive device that received market authorization in
Europe. The company’s second device, RheoPatch, a non-invasive patch, is
in the final stage of development with approval expected in late 2019.

About Luciole Medical

Luciole Medical AG is developing a unique, next-generation platform of
brain monitoring sensors to rapidly provide important information
allowing the proper diagnostic and monitoring of compromised oxygen
supply conditions and complications. The platform also uses a
proprietary complex algorithm to analyse large data sets and extract
clinically relevant information. The company obtained the CE mark for a
minimally invasive probe for ICU and is developing a patch for external
measurement of brain oxygenation parameters. The Swiss-based private
company is a spin-off from the Swiss Polytechnic Institute and the
University of Zürich. For more information, visit http://www.luciolemedical.ch

Contacts

For Luciole Medical:
Dr. Philippe Dro, CEO
Phone: +41
43343 96 04
[email protected]

Media requests for Luciole Medical:
Gretchen Schweitzer or
Dr. Jacob Verghese
Trophic Communications
Phone: +49 89 2388
7730 or +49 173 364 1607
[email protected]